McDermott + Bull has successfully placed Richard Van Bibber as the Vice President of Clinical Affairs at Adagio Medical, Inc. He will be charged with overseeing and managing the company’s sponsored global pre-market and post-market clinical studies and is currently driving the enrollment and completion of Adagio’s newly initiated IDE study.
Richard brings over 20 years of clinical MedTech experience to Adagio Medical. He has worked in pre-clinical, clinical, incubator, start-up, and commercial environments, including four private equity-backed companies. His successful record includes multinational pre-clinical and clinical trial protocols, development of pre-clinical programs, regulatory submissions and approvals, commercialization, raising capital, and strategic and competitive product analysis. Richard has also led efforts to advance life-saving technologies in the cardiovascular and surgical spaces. He received his bachelor’s degree in physiological science from the University of California, Los Angeles and his doctorate in physiology and biophysics from the University of Washington.
Adagio Medical, a privately held medical device company located in Laguna Hills, California, is developing innovative cryoablation technologies that create continuous, transmural lesions to treat cardiac arrhythmias, including paroxysmal and persistent atrial fibrillation, atrial flutter, and ventricular tachycardia. Adagio Medical is a Fjord Ventures portfolio company.